256 related articles for article (PubMed ID: 25442953)
1. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
[TBL] [Abstract][Full Text] [Related]
2. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
Kruithof EK; Schleuning WD
Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
[TBL] [Abstract][Full Text] [Related]
4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
5. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic agents in development.
Verstraete M; Lijnen HR; Collen D
Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
[TBL] [Abstract][Full Text] [Related]
7. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Weitz JI
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
9. [Construction of Pichia pastoris strain expressing salivary plasminogen activator from vampire bat (Desmodus rotundus)].
Liu Y; Su C; Song X; Tang Y; Bao Z
Sheng Wu Gong Cheng Xue Bao; 2009 Apr; 25(4):566-74. PubMed ID: 19637633
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of human tissue-type plasminogen activator (t-PA).
van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
[TBL] [Abstract][Full Text] [Related]
11. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
[TBL] [Abstract][Full Text] [Related]
12. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments.
Davami F; Sardari S; Majidzadeh-A K; Hemayatkar M; Barkhordari F; Enayati S; Adeli A; Mahboudi F
BMB Rep; 2011 Jan; 44(1):34-9. PubMed ID: 21266104
[TBL] [Abstract][Full Text] [Related]
13. Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties.
Saadatirad A; Sardari S; Kazemali M; Zarei N; Davami F; Barkhordari F; Adeli A; Mahboudi F
Mol Biotechnol; 2014 Dec; 56(12):1143-50. PubMed ID: 25143123
[TBL] [Abstract][Full Text] [Related]
14. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
de Vries C; Veerman H; Nesheim ME; Pannekoek H
Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
[TBL] [Abstract][Full Text] [Related]
15. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
Stewart RJ; Fredenburgh JC; Weitz JI
J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
[TBL] [Abstract][Full Text] [Related]
17. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
18. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
Paoni NF; Keyt BA; Refino CJ; Chow AM; Nguyen HV; Berleau LT; Badillo J; Peña LC; Brady K; Wurm FM
Thromb Haemost; 1993 Aug; 70(2):307-12. PubMed ID: 8236140
[TBL] [Abstract][Full Text] [Related]
19. Structural features mediating fibrin selectivity of vampire bat plasminogen activators.
Bringmann P; Gruber D; Liese A; Toschi L; Krätzchmar J; Schleuning WD; Donner P
J Biol Chem; 1995 Oct; 270(43):25596-603. PubMed ID: 7592732
[TBL] [Abstract][Full Text] [Related]
20. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.
Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W
J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
